What is the Purpose of this Study?
Primary - Efficacy To assess the Objective Response Rate (ORR) of ubamatamab alone or in combination with bevacizumab, cemiplimab + fianlimab, or PLD (separately by study arm). Secondary: Efficacy: To assess preliminary efficacy of Ubamatamab combinations as measured by changes to CA-125 response, CR rate, disease control rate (DCR), duration of response (DOR), and progression-free survival (PFS).
Eligibility
- 1. Participants with histologically or cytologically confirmed diagnosis of advanced serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer (clear cell, mucinous, and carcinosarcoma are excluded)
- 2. Must have progression on prior therapy documented radiographically and must have at least 1 measurable lesion (not previously irradiated) that can be accurately measured by RECIST 1.1
- 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- 4. Adequate organ and bone marrow function, as described in the protocol
Where can I participate?
CS Cancer at Cedars-Sinai Medical Center : Abrahm Levi
More about this Clinical Trial
What is the full name of this clinical trial?
R4018-ONC-2445: Multi-Arm Phase 2 study of Ubamatamab with or without additional agents in Platinum - Resistant Ovarian Cancer